FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292823610> ?p ?o ?g. }

• W4292823610 abstract "Abstract Background Previous studies demonstrate a reduced risk of thrombosis and mortality with anticoagulant treatment in patients with COVID-19 than in those without anticoagulation treatment. However, an open question regarding the efficacy and safety of therapeutic anticoagulation (T-AC) versus a lower dose, prophylaxis anticoagulation (P-AC) in COVID-19 patients is still controversial. Methods We systematically reviewed currently available randomized clinical trials (RCTs) and observational studies (OBs) from January 8, 2019, to January 8, 2022, and compared prophylactic and therapeutic anticoagulant treatment in COVID-19 patients. The primary outcomes were risk of mortality, major bleeding, and the secondary outcomes included venous and arterial thromboembolism. Subgroup analysis was also performed between critically ill and non-critically ill patients with COVID-19 and between patients with higher and lower levels of D-dimer. Sensitivity analysis was performed to decrease the bias and the impact of population heterogeneity. Results We identified 11 RCTs and 17 OBs fulfilling our inclusion criteria. In the RCTs analyses, there was no statistically significant difference in the relative risk of mortality between COVID-19 patients with T-AC treatment and those treated with P-AC (RR 0.95, 95% CI, 0.78–1.15, P = 0.60). Similar results were also found in the OBs analyses (RR 1.21, 95% CI, 0.98–1.49, P = 0.08). The pooling meta-analysis using a random-effects model combined with effect sizes showed that in the RCTs and OBs analyses, patients with COVID-19 who received T-AC treatment had a significantly higher relative risk of the major bleeding event than those with P-AC treatment in COVID-19 patients (RCTs: RR 1.76, 95% CI, 1.19–2.62, P = 0.005; OBs: RR 2.39, 95% CI, 1.56–3.68, P < 0.0001). Compared with P-AC treatment in COVID-19 patients, patients with T-AC treatment significantly reduced the incidence of venous thromboembolism (RR 0.51, 95% CI, 0.39–0.67, P <0.00001), but it is not associated with arterial thrombosis events (RR 0.97, 95% CI, 0.66–1.42, P = 0.87). The subgroup analysis of OBs shows that the mortality risk significantly reduces in critically ill COVID-19 patients treated with T-AC compared with those with P-AC treatment (RR 0.58, 95% CI, 0.39–0.86, P = 0.007), while the mortality risk significantly increases in non-critically ill COVID-19 patients treated with T-AC (RR 1.56, 95% CI, 1.34–1.80, P < 0.00001). In addition, T-AC treatment does not reduce the risk of mortality in COVID-19 patients with high d-dimer levels in RCTs. Finally, the overall sensitivity analysis after excluding two RCTs studies remains consistent with the previous results. Conclusions In our integrated analysis of included RCTs and OBs, there is no significant difference between the mortality of T-AC and P-AC treatment in unselected patients with COVID-19. T-AC treatment in COVID-19 patients significantly reduced the incidence of venous thromboembolism but showed a higher risk of bleeding than those with P-AC treatment. In addition, P-AC treatment was superior to T-AC treatment in non-critically ill COVID-19 patients, the evidence supporting the necessity for T-AC treatment in critically ill COVID-19 patients came only from OBs. Trial registration Protocol registration: The protocol was registered at PROSPERO (CRD42021293294). Graphical abstract" @default.
• W4292823610 created "2022-08-24" @default.
• W4292823610 creator A5012603380 @default.
• W4292823610 creator A5016125750 @default.
• W4292823610 creator A5018998672 @default.
• W4292823610 creator A5034238994 @default.
• W4292823610 creator A5038259273 @default.
• W4292823610 creator A5038946248 @default.
• W4292823610 creator A5043490198 @default.
• W4292823610 creator A5050984886 @default.
• W4292823610 creator A5055664053 @default.
• W4292823610 creator A5071725079 @default.
• W4292823610 creator A5079845418 @default.
• W4292823610 date "2022-08-23" @default.
• W4292823610 modified "2023-10-01" @default.
• W4292823610 title "Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis" @default.
• W4292823610 cites W1965492206 @default.
• W4292823610 cites W1978895866 @default.
• W4292823610 cites W1984246714 @default.
• W4292823610 cites W2018856451 @default.
• W4292823610 cites W2098923148 @default.
• W4292823610 cites W2122779695 @default.
• W4292823610 cites W2125435699 @default.
• W4292823610 cites W2137975307 @default.
• W4292823610 cites W2225937646 @default.
• W4292823610 cites W2313923699 @default.
• W4292823610 cites W2588681363 @default.
• W4292823610 cites W2754847785 @default.
• W4292823610 cites W2976369321 @default.
• W4292823610 cites W2989714602 @default.
• W4292823610 cites W3012860481 @default.
• W4292823610 cites W3015656121 @default.
• W4292823610 cites W3021176980 @default.
• W4292823610 cites W3027918021 @default.
• W4292823610 cites W3028989873 @default.
• W4292823610 cites W3035643679 @default.
• W4292823610 cites W3081515108 @default.
• W4292823610 cites W3087656790 @default.
• W4292823610 cites W3092252175 @default.
• W4292823610 cites W3095441802 @default.
• W4292823610 cites W3096414087 @default.
• W4292823610 cites W3096815097 @default.
• W4292823610 cites W3107284527 @default.
• W4292823610 cites W3108597594 @default.
• W4292823610 cites W3109513293 @default.
• W4292823610 cites W3110333120 @default.
• W4292823610 cites W3112577329 @default.
• W4292823610 cites W3115509726 @default.
• W4292823610 cites W3118615836 @default.
• W4292823610 cites W3120028189 @default.
• W4292823610 cites W3120385498 @default.
• W4292823610 cites W3122174631 @default.
• W4292823610 cites W3124817318 @default.
• W4292823610 cites W3131028610 @default.
• W4292823610 cites W3132355904 @default.
• W4292823610 cites W3135868073 @default.
• W4292823610 cites W3136016654 @default.
• W4292823610 cites W3153748994 @default.
• W4292823610 cites W3165656738 @default.
• W4292823610 cites W3172155398 @default.
• W4292823610 cites W3174040578 @default.
• W4292823610 cites W3180828297 @default.
• W4292823610 cites W3194544920 @default.
• W4292823610 cites W3197505420 @default.
• W4292823610 cites W3200879206 @default.
• W4292823610 cites W3202637221 @default.
• W4292823610 cites W3203603084 @default.
• W4292823610 cites W3205091111 @default.
• W4292823610 cites W3205387447 @default.
• W4292823610 cites W3206263576 @default.
• W4292823610 cites W3206483794 @default.
• W4292823610 cites W3216021979 @default.
• W4292823610 cites W4200078625 @default.
• W4292823610 cites W4200137171 @default.
• W4292823610 cites W4200320437 @default.
• W4292823610 cites W4200557111 @default.
• W4292823610 cites W4205922819 @default.
• W4292823610 cites W4206945239 @default.
• W4292823610 cites W4210755204 @default.
• W4292823610 cites W4211215834 @default.
• W4292823610 cites W4220884954 @default.
• W4292823610 cites W4226146026 @default.
• W4292823610 cites W4231969161 @default.
• W4292823610 doi "https://doi.org/10.1186/s12959-022-00408-9" @default.
• W4292823610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35999599" @default.
• W4292823610 hasPublicationYear "2022" @default.
• W4292823610 type Work @default.
• W4292823610 citedByCount "4" @default.
• W4292823610 countsByYear W42928236102022 @default.
• W4292823610 countsByYear W42928236102023 @default.
• W4292823610 crossrefType "journal-article" @default.
• W4292823610 hasAuthorship W4292823610A5012603380 @default.
• W4292823610 hasAuthorship W4292823610A5016125750 @default.
• W4292823610 hasAuthorship W4292823610A5018998672 @default.
• W4292823610 hasAuthorship W4292823610A5034238994 @default.
• W4292823610 hasAuthorship W4292823610A5038259273 @default.
• W4292823610 hasAuthorship W4292823610A5038946248 @default.
• W4292823610 hasAuthorship W4292823610A5043490198 @default.
• W4292823610 hasAuthorship W4292823610A5050984886 @default.
• W4292823610 hasAuthorship W4292823610A5055664053 @default.

• next